Group 1 - The core point of the article is that 加科思-B (01167) experienced a 5.04% increase in stock price, reaching 7.50 HKD, with a trading volume of 42.24 million HKD [1] - The company announced that it will present preclinical data on its Pan-KRAS inhibitor JAB-23E73 at the 2025 American Association for Cancer Research International Molecular Targets and Cancer Therapeutics Conference in Boston from October 22 to October 26, 2025 [1] - 加科思 has signed an agreement with 海松资本 and an industry partner for a capital increase and equity transfer, where 海松资本 will pay 125 million RMB as an initial payment and 75 million RMB as a milestone payment to acquire 80% of 加科瑞康, reducing 加科思's stake in 加科瑞康 to 10% [1] Group 2 - The divestment of non-core assets allows the company to focus more strategically on the oncology field and enhances its cash flow [1]
加科思-B午前涨超5% 公司发表抑制剂JAB-23E73临床前数据